Clene (NASDAQ:CLNN) and Shineco (NASDAQ:SISI) Head to Head Survey

Shineco (NASDAQ:SISI) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Shineco and Clene”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shineco	$9.60 million	0.00	-$22.45 million	($204.00)	-0.00
Clene	$200,000.00	265.00	-$26.17 million	($3.50)	-1.17

Shineco has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Shineco and Clene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shineco	-380.55%	-79.89%	-33.01%
Clene	-20,063.96%	N/A	-137.04%

Insider & Institutional Ownership

4.1% of Shineco shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 0.0% of Shineco shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Shineco and Clene, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shineco	1	0	0	0	1.00
Clene	1	0	6	0	2.71

Clene has a consensus target price of $34.00, indicating a potential upside of 733.33%. Given Clene’s stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Shineco.

Volatility and Risk

Shineco has a beta of -1.76, meaning that its stock price is 276% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Summary

Clene beats Shineco on 9 of the 14 factors compared between the two stocks.

About Shineco

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.